Literature DB >> 9322895

Frequent hepatic involvement in adult T cell leukemia: comparison with non-Hodgkin's lymphoma.

Y Yamada1, S Kamihira, K Murata, M Yamamura, T Maeda, K Tsukasaki, T Jubash, S Atogami, H Sohda, T Taguchi, M Tomonaga.   

Abstract

We examined 111 patients with acute type- or lymphoma type-adult T-cell leukemia (ATL) and compared them with 106 patients with non-Hodgkin's lymphoma (NHL). In addition to skin involvement and hypercalcemia which are already known to be frequent in ATL, ATL patients showed an higher incidence of hepatic involvement. There was more frequent palpable hepatomegaly, higher total bilirubin, GOT, GPT, lactate dehydrogenase (LDH), and alkaline phosphatase values in ATL than in NHL patients (p < 0.0001). Among 36 autopsied liver samples, invasion of ATL cells was confirmed in 22 cases. ATL patients with impaired hepatic function showed shorter survival times than patients without hepatic dysfunction. Moreover, ATL patients showed a worse performance status (PS), a higher incidence of lytic bone lesions, lower total protein (TP) and serum albumin levels than NHL patients. This invasive characters of ATL cells and consequent impaired general condition seemed to be factors affecting the poor prognosis recorded in ATL.

Entities:  

Mesh:

Year:  1997        PMID: 9322895     DOI: 10.3109/10428199709051782

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  2 in total

1.  A network biology approach evaluating the anticancer effects of bortezomib identifies SPARC as a therapeutic target in adult T-cell leukemia cells.

Authors:  Junko H Ohyashiki; Ryoko Hamamura; Chiaki Kobayashi; Yu Zhang; Kazuma Ohyashiki
Journal:  Adv Appl Bioinform Chem       Date:  2008-10-30

2.  Acute Liver Injury Due to T-cell Infiltration into the Liver as an Initial Clinical Finding of Adult T-cell Leukemia/Lymphoma.

Authors:  Keisuke Kakisaka; Yuji Suzuki; Shugo Kowata; Shigeki Ito; Yasuhiro Takikawa
Journal:  Intern Med       Date:  2021-08-01       Impact factor: 1.271

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.